Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cefotan
(United States) [Available]Synonyms :
cefotetan
Class :
Cephalosporins and 2nd Generation
Brand Name :
Cefotan
(United States) [Available]Synonyms :
cefotetan
Class :
Cephalosporins and 2nd Generation
Dosage Forms & Strengths
Injectable solution
20mg per ml
40mg per ml
powder for injection
1g
2g
10g
1-2 g IV or IM every 12hrs for moderate infections
2 g IV every 12hrs for Severe infections
3 g IV every 12hrs for Life-threatening infections
The maximum duration of therapy is 7-14 days
1-2 g IV or IM every 12hrs for moderate infections
2 g IV every 12hrs for Severe infections
3 g IV every 12hrs for Life-threatening infections
The maximum duration of therapy is 7-14 days
1-2 g IV or IM every 12hrs for moderate infections
2 g IV every 12hrs for Severe infections
3 g IV every 12hrs for Life-threatening infections
The maximum duration of therapy is 3-4 weeks
1-2 g IV or IM every 12hrs for moderate infections
2 g IV every 12hrs for Severe infections
3 g IV every 12hrs for Life-threatening infections
The maximum duration of therapy is seven days
1-2 g IV or IM every 12hrs for moderate infections
2 g IV every 12hrs for Severe infections
3 g IV every 12hrs for Life-threatening infections
The maximum duration of therapy is 14 days
Dosage Forms & Strengths
injectable solution
20mg per ml
40mg per ml
powder for injection
1g
2g
10g
Age:> 1year
20-40 mg per kg IV or IM given every 12hrs
Surgical Prophylaxis:
Age:> 1year
40 mg per kg IV once 30-60 minutes before surgery
but in some cases, if ruptured viscus was seen, gentamicin 2 mg per kg may be added
when both drugs are combined, there may be an increased risk of adverse effects
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
when both drugs are combined, there may be an increased effect of argatroban by anticoagulation
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine
when both drugs are combined, there may be an increased effect of bivalirudin by anticoagulation
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine
when both drugs are combined, there may be an increased effect of dalteparin by anticoagulation
when both drugs are combined, there may be an increased effect of enoxaparin by anticoagulation
when both drugs are combined, there may be an increased effect of fondaparinux by anticoagulation
when both drugs are combined, there may be an increased effect of heparin by anticoagulation
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
it may diminish the excretion rate when combined with estradiol valerate resulting in a greater serum level
It may enhance the risk of nephrotoxicity when combined with phenylbutazone
When cefotetan is used together with piroxicam, this leads to increased risk or seriousness of nephrotoxicity
When cefmenoxime is used together with cefotetan, this leads to enhanced risk or seriousness of nephrotoxicity
When cefotetan is used together with proglumetacin, this leads to enhanced risk or seriousness of nephrotoxicity
may have an increased nephrotoxic effect when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may have an increased nephrotoxic effect when combined with aminoglycosides
When Cefotetan is used together with benoxaprofen, this leads to enhanced risk or seriousness of nephrotoxicity
cefotetan leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefotetan leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
cefotetan leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
cefotetan leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefotetan leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When cefotetan is used together with difenpiramide, this leads to enhanced risk or seriousness of nephrotoxicity
cefotetan may decrease the excretion rate of almasilate, leading to higher serum levels
it increases the nephrotoxicity of cephalosporins
may increase the nephrotoxic effect of cephalosporins
neomycin/polymyxin B/bacitracin topical
may increase the nephrotoxic effect of cephalosporins
may increase the nephrotoxic effect of cephalosporins
may increase the nephrotoxic effect of cephalosporins
may increase the nephrotoxic effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
cefotetan might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
choline magnesium trisalicylate
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
Actions and Spectrum:
Action:
Cefotetan has the ability to bind and block the penicillin protein binding sites which are responsible for cell wall production. Compared to cephalosporins first- and second-generation drugs this is more powerful against Gram-negative bacteria.
Frequency defined
<10%
Hypersensitivity reaction
Hepatic enzyme elevation
Diarrhea
<1%
Neutropenia
Prolongation of bleeding time
Thrombocytopenia
Contraindication/Caution:
Contraindications include hypersensitivity to few drugs, potential risk of bleeding disorders.
Pregnancy/Lactation:
Pregnancy warnings:
US FDA pregnancy category: B
Breastfeeding warnings:
The release of the drug into human breastmilk is known.
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits Hence these categories of drugs need to be avoided by pregnant women
Category N: There is no data available for the drug under this category
Pharmacology:
Cefotetan is effective against a wide variety of aerobic and anaerobic pathogens that has a high level of resistance to a broad spectrum of beta-lactamases.
Pharmacodynamics:
Cefotetan inhibits the proteins binding to the penicillin which involves in cell wall production and resulting in bactericidal activity.
Pharmacokinetics:
Absorption
Rapidly absorbed.
Distribution
This has 88% plasma protein binding.
Metabolism
Cefotetan is not significantly metabolized.
Excretion and Elimination
Primarily excreted in urine with a half-life of 3 to 4.6 hours.
Administration:
The route of administration is intravenous/intramuscular for 7-14 days.
Patient Information Leaflet
Generic Name: cefotetan
Why do we use cefotetan?
Cefotetan is used for the prophylaxis and treatment of various bacterial infections.
It is indicated to treat urinary tract infections, bone and joint infection, and lower respiratory tract infections.
It is also used before and during some surgeries to help prevent infection. It is an antibiotic drug works that stops the growth of bacteria.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
